

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

**VOLUNTARY ANNOUNCEMENT –  
TERMINATION OF PROMOTION COOPERATION WITH  
ASTRAZENECA PHARMACEUTICAL**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.\* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the voluntary announcement of the Company dated 1 March 2021 and the overseas regulatory announcement of the Company dated 4 January 2022.

On 28 February 2021, the Company entered into an exclusive promotion agreement (the “**Original Agreement**”) with AstraZeneca Pharmaceutical Co., Ltd. (“**AstraZeneca Pharmaceutical**” or the “**Promoter**”), pursuant to which the Company granted AstraZeneca Pharmaceutical the exclusive promotion right of Toripalimab Injection (trade name: TUOYI®) for the urinary cancer indications to be approved subsequently for marketing in mainland China and the exclusive promotion right for all indications approved and to be approved in non-core urban areas. The Company continues to be responsible for the promotion of other indications approved and to be approved excluding urinary cancer indications in core urban areas.

As the Company’s self-built commercialization team has gradually matured, more indications of Toripalimab Injection have been successfully included in the latest version of the National Reimbursement Drug List. In order to better implement the Company’s next stage of development in relation to its promotion strategy for product commercialization and actively cope with the future market competition landscape, after friendly negotiation between the parties, on 31 December 2021, the Company and AstraZeneca Pharmaceutical entered into a termination agreement in respect of the Original Agreement (the “**Termination Agreement**”), pursuant to which the Original Agreement was terminated with effect from 1 January 2022 (the “**Termination Date**”) and the Company withdrew the promotion right of Toripalimab Injection as agreed in the Original Agreement. The commercialization team of the Company will be responsible for all promotion activities of Toripalimab Injection in mainland China.

**SUBSEQUENT WORK ARRANGEMENTS**

- I. Termination of the promotion authorization: the authorization of the Company obtained by the Promoter under the Original Agreement shall be terminated and the Promoter shall no longer promote Toripalimab Injection. If the Promoter entrusted any sub-licensee to carry out the promotion (whether in the name of the Company or in the name of the Promoter), the Promoter shall ensure that such sub-licensee has terminated the promotion activities in the name of the Company or the Promoter from the Termination Date.

- II. The parties shall actively communicate and negotiate to deal with the matters not addressed under the Original Agreement and the handover arrangement, and sign supplemental agreements for confirming the outstanding matters.

## **IMPACT OF ENTERING INTO THE TERMINATION AGREEMENT ON THE COMPANY**

The sales volume of Toripalimab Injection has been mainly concentrated in the core urban areas since its launch, while the sales volume in non-core urban areas accounts for a small proportion of the overall sales volume. In addition, the inclusion of two new indications of Toripalimab Injection in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021 Edition) will be conducive to the further promotion of the marketing of such drug and the increase in overall sales scale. The commercialization team of the Company will continue to be responsible for all the promotion activities of Toripalimab Injection in mainland China and place more promotion efforts in non-core urban areas. The termination of the promotion cooperation was based on the decision made by the parties after friendly negotiation, prudent judgment and thorough communication and is not expected to have material adverse impact on the financial position and operating results of the Company, nor will it prejudice the interests of the Company and its shareholders.

## **RISK WARNING**

Upon signing of the Termination Agreement, the Company and the Promoter will arrange for handover of the documents, information and market, which may affect the sales activities of the Company in the short term and result in uncertainties about the impact on the profit of the Company. Investors are advised to make cautious decisions and pay careful attention to investment risks.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 4 January 2022

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.*

\* For identification purpose only